Targeted Therapy in Nonmelanoma Skin Cancers

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2013 Nov 12

PMID 24212808

Citations 7

Authors

Giulia Spallone

Elisabetta Botti

Antonio Costanzo

Affiliations

Soon will be listed here.

Abstract

Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in light-skinned populations, and includes mainly Basal Cell Carcinomas (BCC), representing around 75% of NMSC and Squamous Cell Carcinomas (SCC). The incidence of these tumors is continuously growing. It was found that the overall number of procedures for NMSC in US rose by 76%, from 1,158,298 in 1992 to 2,048,517 in 2006. Although mortality from NMSC tends to be very low, clearly the morbidity related to these skin cancers is very high. Treatment options for NMSC include both surgical and nonsurgical interventions. Surgery was considered the gold standard therapy, however, advancements in the knowledge of pathogenic mechanisms of NMSCs led to the identification of key targets for drug intervention and to the consequent development of several targeted therapies. These represent the future in treatment of these common forms of cancer ensuring a high cure rate, preservation of the maximal amount of normal surrounding tissue and optimal cosmetic outcome. Here, we will review recent advancements in NMSC targeted therapies focusing on BCC and SCC.

Citing Articles

Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers.

Howard A, Bojko J, Flynn B, Bowen S, Jungwirth U, Walko G Exp Dermatol. 2022; 31(10):1477-1499.

PMID: 35913427 PMC: 9804452. DOI: 10.1111/exd.14655.

Construction and evaluation of an efficient C-Jun siRNA to downregulate matrix metalloproteinase in human keratinocytes and fibroblasts under UV exposure.

Xiao H, Yang R, Yang F, Zhao Y, Liu Y Mol Genet Genomic Med. 2019; 8(1):e1047.

PMID: 31729200 PMC: 6978249. DOI: 10.1002/mgg3.1047.

The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin.

Rognoni E, Walko G Cells. 2019; 8(5).

PMID: 31058846 PMC: 6562585. DOI: 10.3390/cells8050411.

A Retrospective Study of the Diagnostic Accuracy of In Vivo Reflectance Confocal Microscopy for Basal Cell Carcinoma Diagnosis and Subtyping.

Lupu M, Popa I, Voiculescu V, Boda D, Caruntu C, Zurac S J Clin Med. 2019; 8(4).

PMID: 30987174 PMC: 6518285. DOI: 10.3390/jcm8040449.

SOCS3 inhibits the pathological effects of IL-22 in non-melanoma skin tumor-derived keratinocytes.

Madonna S, Scarponi C, Morelli M, Sestito R, Scognamiglio P, Marasco D Oncotarget. 2017; 8(15):24652-24667.

PMID: 28445952 PMC: 5421877. DOI: 10.18632/oncotarget.15629.

References

Xie J, Murone M, Luoh S, Ryan A, Gu Q, Zhang C . Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998; 391(6662):90-2. DOI: 10.1038/34201. View

Fischer C, Zlobec I, Stockli E, Probst S, Storck C, Tornillo L . Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas. Hum Pathol. 2008; 39(10):1527-34. DOI: 10.1016/j.humpath.2008.03.001. View

Madson J, Lynch D, Svoboda J, Ophardt R, Yanagida J, Putta S . Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis. Am J Pathol. 2009; 174(6):2357-66. PMC: 2684199. DOI: 10.2353/ajpath.2009.080638. View

Park Y, Younes M, Jasser S, Yigitbasi O, Zhou G, Bucana C . AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res. 2005; 11(5):1963-73. DOI: 10.1158/1078-0432.CCR-04-1665. View

Kinzler K, Bigner S, Bigner D, Trent J, Law M, OBrien S . Identification of an amplified, highly expressed gene in a human glioma. Science. 1987; 236(4797):70-3. DOI: 10.1126/science.3563490. View

Burtness B, Goldwasser M, Flood W, Mattar B, Forastiere A . Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005; 23(34):8646-54. DOI: 10.1200/JCO.2005.02.4646. View

Rowe D, Carroll R, Day Jr C . Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992; 26(6):976-90. DOI: 10.1016/0190-9622(92)70144-5. View

Couve-Privat S, Bouadjar B, Avril M, Sarasin A, Daya-Grosjean L . Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. Cancer Res. 2002; 62(24):7186-9. View

Abd El-Rehim D, Pinder S, Paish C, Bell J, Rampaul R, Blamey R . Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004; 91(8):1532-42. PMC: 2410019. DOI: 10.1038/sj.bjc.6602184. View

10.

Rudin C, Hann C, Laterra J, Yauch R, Callahan C, Fu L . Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009; 361(12):1173-8. PMC: 5317279. DOI: 10.1056/NEJMoa0902903. View

11.

Kricker A, Armstrong B, English D, Heenan P . A dose-response curve for sun exposure and basal cell carcinoma. Int J Cancer. 1995; 60(4):482-8. DOI: 10.1002/ijc.2910600410. View

12.

Gailani M, Leffell D, Glynn M, Zaphiropoulos P, Pressman C, Unden A . The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996; 14(1):78-81. DOI: 10.1038/ng0996-78. View

13.

Baker C, Kedar D, McCarty M, Tsan R, Weber K, Bucana C . Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol. 2002; 161(3):929-38. PMC: 1867249. DOI: 10.1016/S0002-9440(10)64253-8. View

14.

Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D . Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002; 62(4):1030-5. View

15.

Hahn H, Wicking C, Zaphiropoulous P, Gailani M, Shanley S, Chidambaram A . Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996; 85(6):841-51. DOI: 10.1016/s0092-8674(00)81268-4. View

16.

de Sevaux R, Smit J, de Jong E, van de Kerkhof P, Hoitsma A . Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol. 2003; 49(3):407-12. DOI: 10.1067/s0190-9622(03)01831-0. View

17.

Reifenberger J, Wolter M, Weber R, Megahed M, Ruzicka T, Lichter P . Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1998; 58(9):1798-803. View

18.

Khandwala H, McCutcheon I, Flyvbjerg A, Friend K . The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000; 21(3):215-44. DOI: 10.1210/edrv.21.3.0399. View

19.

Saltz L, Meropol N, Loehrer Sr P, Needle M, Kopit J, Mayer R . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22(7):1201-8. DOI: 10.1200/JCO.2004.10.182. View

20.

Morgillo F, Kim W, Kim E, Ciardiello F, Hong W, Lee H . Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007; 13(9):2795-803. DOI: 10.1158/1078-0432.CCR-06-2077. View